¿¬¼ö°­ÁÂ
2022 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2022-04-16
2022 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2022-04-16
±³À°ÀÏÀÚ : 2022-04-16
±³À°Àå¼Ò : ÇÏÀ̺긮µå (Àå¼Ò: ¹é¹ü±è±¸±â³ä°ü)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà) 2022 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ 
´ã´çÀÚ : ±èÁÖ¿Á
¿¬¶ôó : 02-587-7462  
À̸ÞÀÏ : secretkda@thedementia.co.kr      
±³À°Á¾·ù : ½Å°æ°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 15ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í ÀϹÝȸ¿ø 2¸¸¿ø, Á¤È¸¿ø 3¸¸¿ø, ºñȸ¿ø 5¸¸¿ø (ÇöÀåµî·Ï ¾øÀ½)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 08:50~09:00 Opening remarks  () 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:00~09:20 Genetics Update  ¹Ú¿µÈ£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:20~09:40 Microbiome Update  ÀÌ°ÇÈ£(Á¶¼±´ëÇб³) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:40~10:05 The Gantenerumab Global Development Program for Alzheimer''''s Disease  Scott Schobel(Roche) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:05~10:30 Clinical, Biomarker, and Safety Update BAN2401-G000-201, the Lecanemab Phase 2 Proof of Concept Study and Open Label Extension  Chad Swanson(Eisai) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:30~10:55 Future for the development of Alzheimer¡¯s disease modifiers clinical trial results of donanemab  Ena Oru(Lilly) 
È޽Ġ04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:55~11:20 Coffee Break  () 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:20~12:00 Can we prevent aging?  ÇѼ³Èñ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:00~12:40 Current and future direction of AD biomarkers  Gill Rabinovici(UCSF) 
±âŸ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:40~13:00 ÃÑȸ  () 
½Ä»ç 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 13:00~14:20 Lunch ¹× Poster session  () 
Åä·Ð 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 14:20~15:20 Pannel discussion for Current Issues : Aducanumab! Is this new hope for Alzhiemer's?  ¹Ú±âÇü(°¡ÃµÀÇ´ë) 
È޽Ġ04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 15:20~15:30 Coffee Break  () 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 15:30~15:50 Development of tau-targeted therapeutic strategy for dementia  ±èÀ±°æ(KIST) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 15:50~16:10 Nanobiosensor technology for serological biomarker detection of neurodegenerative disease  È²±³¼±(°æÈñÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 16:10~16:30 Genetic factors of Alzheimer's disease in the Korean population  ±èÈñÁø(¼º±Õ°üÀÇ´ë) 
È޽Ġ04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 16:30~16:40 Coffee Break  () 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 16:40~17:00 Clinical usefulness and need of blood biomarkers in the diagnosis and follow-up of AD  °í¼ºÈ£(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 17:00~17:20 Introduction of Currently Available Blood Based Biomarker of AD  ÀåÀç¿ø(°­¿øÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 17:20~17:40 Clinical application of AD blood biomarker: expectations & concerns  ½É¿ë¼ö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 15:30~15:50 Clinical application of A.I. in Dementia  ¼­»ó¿ø(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 15:50~16:10 A.I in Neuroimaging of AD  Á¤¿ë(KAIST) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 16:10~16:30 Dementia big data platforms in the UK, Europe and Korea  ±èÄ¡Çå(ÇѸ²ÀÇ´ë) 
È޽Ġ04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 16:30~16:40 Coffee Break  () 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 16:40~17:00 µðÁöÅÐ Ä¡·áÁ¦ÀÇ Çö¾È°ú ¹Ì·¡  ÇÑ¿µ¹Î ÁÖ¹«°ü(½ÄÇ°ÀǾàÇ°¾ÈÀüó) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 17:00~17:20 µðÁöÅÐ Ä¡·áÁ¦ °³¹ß°ú ÇâÈÄ Àü¸Á  ±èÁø¿ì ´ëÇ¥(¢ßÇÏÀÌ) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 17:20~17:40 µðÁöÅÐÇコÄɾî/µðÁöÅÐÄ¡·áÁ¦´Â ¾î¶»°Ô ºñÁö´Ï½º°¡ µÇ´Â°¡  ±èÄ¡¿ø »ó¹«(Ä«Ä«¿Àº¥Ã³½º) 
±âŸ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 17:40~17:50 Closing remarks ¹× ½Ã»ó½Ä  () 
  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[Á¦ÁÖ] 2024³â ´ëÇѳúÁ¹ÁßÇÐȸ Ãá°èÇмú´ëȸ : 2024-04-20

±³À°ÀÏÀÚ : 2024-04-20 ±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ Á¦ÁÖ ±³À°ÁÖÁ¦ : 2024³â ´ëÇѳúÁ¹ÁßÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇѳúÁ¹ÁßÇÐȸ ´ã´çÀÚ : ±èÈñ¿µ ¿¬¶ôó : 0502-27

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,486 , ´ñ±Û¼ö : 0

[¼­¿ï] 2024³â Á¦11ȸ °­µ¿°æÈñ ºñ´¢ÀÇÇаú ½ÉÆ÷Áö¾ö : 2024-04-20

±³À°ÀÏÀÚ : 2024-04-20 ±³À°Àå¼Ò : °­µ¿°æÈñ´ëÇб³º´¿ø º°°üµ¿ 4Ãþ Â÷ÈÄ¿µÈ¦ ±³À°ÁÖÁ¦ : 2024³â Á¦11ȸ °­µ¿°æÈñ ºñ´¢ÀÇÇаú ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : °­µ¿°æÈñ´ëÇб³º´¿ø ½Ã

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,324 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) Á¦9ȸ ºñ¸¸Àü¹®°¡ ±âÃÊ°úÁ¤ : 2024-04-28

±³À°ÀÏÀÚ : 2024-04-28 ±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) Á¦9ȸ ºñ¸¸Àü¹®°¡ ±âÃÊ°úÁ¤ ÁÖÃÖ±â°ü : ´ëÇѺñ¸¸ÇÐȸ ´ã´çÀÚ : ÃÖÀ±Áö ¿¬¶ôó : 02-6941-087

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,446 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) 2024³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (4¿ù) : 2024-04-20

±³À°ÀÏÀÚ : 2024-04-20 ±³À°Àå¼Ò : ¿Â¶óÀÎ (24½Ã°£ VOD ´çÀÏ ¼ÛÃâ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (4¿ù)ÁÖÃÖ±â°ü : ¼­¿ïƯ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,478 , ´ñ±Û¼ö : 1

[´ëÀü] 2024 ´ëÇѳ»½Ã°æ·Îº¿¿Ü°úÇÐȸ Ãá°è Çмú´ëȸ ¹× 14ȸ ±¹Á¦½ÉÆ÷Áö¿ò (KSERS 2024)(1ÀÏÂ÷) : 2024-04-11

±³À°ÀÏÀÚ : 2024-04-11 ±³À°Àå¼Ò : ´ëÀüÄÁº¥¼Ç¼¾ÅÍ Á¦1Àü½ÃÀå ±³À°ÁÖÁ¦ : (¿ÀÇÁ¶óÀÎ)2024 ´ëÇѳ»½Ã°æ·Îº¿¿Ü°úÇÐȸ Ãá°è Çмú´ëȸ ¹× 14ȸ ±¹Á¦½ÉÆ÷Áö¿ò (KSERS 2

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,496 , ´ñ±Û¼ö : 0